Skip to main content
Clinical Trials/NCT05563259
NCT05563259
Enrolling By Invitation
Not Applicable

The Cross-sectional and Longitudinal Study of Relationship Between Non-alcoholic Fatty Liver Disease and Cognitive Impairment

Yan Bi1 site in 1 country500 target enrollmentMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-Alcoholic Fatty Liver Disease
Sponsor
Yan Bi
Enrollment
500
Locations
1
Primary Endpoint
Cognitive Assessment (MMSE)
Status
Enrolling By Invitation
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to explore the relationship between Non-alcoholic fatty liver disease and cognitive impairment and evaluate the effect of metabolic surgery or lifestyle intervention on cognition.

Detailed Description

Previous research has shown that Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cognitive impairment. Even though there are many noninvasive tests available, a liver biopsy is still required for the accurate diagnosis of NAFLD. However, there are now few studies on cognitive function in patients with NAFLD based on pathological diagnosis. On one hand, in the cross-sectional study, biometric measurements, cognitive assessment, magnetic resonance imaging (MRI) results are analysed to explore the differences among control subjects and NAFLD patients undergoing liver biopsy. One the other hand, in the longitudinal study, changes in cognitive scales and MRI results in NAFLD patients both at baseline and 12-48 months after intervention are collected to investigate whether surgical intervention and weight control benefit brain function.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
September 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Yan Bi
Responsible Party
Sponsor Investigator
Principal Investigator

Yan Bi

Chief Physician

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Eligibility Criteria

Inclusion Criteria

  • \>6 years of education
  • right handed

Exclusion Criteria

  • consumed excessive alcohol (≥140 g/week for males or ≥ 70 g/week for females)
  • with history of other liver diseases including chronic hepatitis, biliary obstructive diseases or autoimmune hepatitis
  • with thyroid diseases
  • in a state of anxiety or depression
  • inability to complete cognitive function scales

Outcomes

Primary Outcomes

Cognitive Assessment (MMSE)

Time Frame: 1 day

Mini-Mental State Examination (MMSE) scores from 0-30, and the test means better cognition with a higher score.

Physical assessments.

Time Frame: 1 day

BMI (body mass index) in kg/m\^2

Participants' personal information

Time Frame: 1 day

Self-reported information (age in years, gender, education in years)

Cognitive Assessment (MoCA)

Time Frame: 1 day

he Montreal Cognitive Assessment (MoCA) scores from 0-30, and the test means better cognition with a higher score.

Cognitive Assessment (RBANS)

Time Frame: 1 day

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores from 0-800, and the test means better cognition with a higher score.

brain activation in fMRI

Time Frame: 1 day

All patients underwent odor-induced task fMRI on a 3.0T MR scanner with 222 volumes for task fMRI and 230 volumes for resting-state and functional fMRI. The odor-induced task consisted of "fresh air" "rest" and "scent". Odor-induced brain activation was assessed by a general linear model using Statistical Parametric Mapping 12 (SPM12) software. Following extraction of the three separate conditions "fresh air," "scent," and "rest" from the whole sequence, contrasts were made for each participant between "fresh air \> rest" and "scent \> rest." Odor-induced fMRI data were analyzed in the mask of the olfactory network, including the regions of bilateral parahippocampus, amygdala, piriform cortex, insula, orbitofrontal cortex, hippocampus, and entorhinal cortices.

Secondary Outcomes

  • Change of Cognitive Assessment (MMSE) from baseline(12-48 months)
  • Change of brain MRI measurement from baseline(12-48 months)
  • Change of weight from baseline(12-48 months)
  • Change of Cognitive Assessment (RBANS) from baseline(12-48 months)
  • Change of Cognitive Assessment (MoCA) from baseline(12-48 months)

Study Sites (1)

Loading locations...

Similar Trials